Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) shot up 5.2% during mid-day trading on Friday . The stock traded as high as $4.45 and last traded at $4.42, with a volume of 182,044 shares changing hands. The stock had previously closed at $4.20.

Several research firms have issued reports on TTPH. Wedbush lowered their price objective on shares of Tetraphase Pharmaceuticals from $8.00 to $4.00 and set an “outperform” rating for the company in a research report on Friday, May 13th. Gabelli cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating and set a $7.00 price objective for the company. in a research report on Friday, May 13th. Zacks Investment Research cut shares of Tetraphase Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday. Needham & Company LLC reaffirmed a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Saturday, May 14th. Finally, BMO Capital Markets started coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, April 11th. They issued a “market perform” rating and a $8.00 price target for the company. Twelve equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $20.80.

The stock’s 50-day moving average price is $4.19 and its 200 day moving average price is $4.91. The company’s market cap is $160.33 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its quarterly earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.46) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by $0.02. The business had revenue of $2 million for the quarter, compared to analyst estimates of $2.20 million. During the same period in the previous year, the company posted ($0.66) EPS. Tetraphase Pharmaceuticals’s revenue was down 33.3% on a year-over-year basis. Equities research analysts expect that Tetraphase Pharmaceuticals Inc. will post ($1.96) earnings per share for the current fiscal year.

An institutional investor recently raised its position in Tetraphase Pharmaceuticals stock. California Public Employees Retirement System increased its position in shares of Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) by 1,459.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 276,000 shares of the biopharmaceutical company’s stock after buying an additional 258,300 shares during the period. California Public Employees Retirement System owned 0.76% of Tetraphase Pharmaceuticals worth $2,768,000 as of its most recent SEC filing.

Tetraphase Pharmaceuticals, Inc (Tetraphase) is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. It is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.